Aggressive Treatment of Metabolic Syndrome in Patients Receiving Clozapine for Schizophrenia

Stopped early · Not applicable

Conditions studied: Metabolic Syndrome

In brief

Schizophrenia patients treated with clozapine have a high prevalence of obesity-related metabolic syndrome. The condition is often poorly treated and may lead to the emergence of coronary heart disease and type 2 diabetes. The study will investigate whether structured treatment provided at the site of the outpatient psychiatric clinic of metabolic syndrome in this population will decrease the severity of metabolic syndrome as compared with usual care received by these patients in the community.

Key facts

Study ID

NCT00794963

Run by

Northwell Health

People needed

8

Starts

2008-11-01

Expected to finish

2010-05-01

Last updated by the study team

2015-04-15

Who can join

Age: 19 and older, up to 79. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• patients with schizophrenia treated with clozapine; age 19-79

You may not qualify if…

• pregnant women, personal history of/or comorbid eating disorders

Where it is running

• Zucker Hillside Hospital — Glen Oaks, New York, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.